Therapeutic and Safety Evaluation of A Compound Unani Formulation along with Roghan e Zaitoon in the Management of Shara (Chronic Urticaria) A Randomized open label Comparative clinical study.

Allergic diseases such as urticaria pose a major challenge in terms of diagnosis and management. Urticaria significantly affects the quality of life and is marked by wheals, redness, and itching. Acute urticaria lasts less than six weeks, while chronic urticaria persists longer, commonly affecting middle aged women. Though mast cell activation and histamine release are recognized mechanisms, the exact cause remains unclear. Modern medicine provides symptomatic relief with antihistamines, corticosteroids, and leukotriene antagonists, but these are costly, associated with side effects like drowsiness, headache, and systemic complications, and do not offer a permanent cure.

In Unani medicine, urticaria is described as Shara, attributed mainly to fasad e dam due to excess bile or abnormal phlegm. Various single and compound formulations are traditionally used with good safety and effectiveness. To evaluate this approach, a clinical study was designed using a compound Unani formulation and Roghan e Zaitoon.

The compound formulation will be administered orally in a dose of 6.125 g twice daily after meals. It consists of Faudanj (Mentha arvensis, 7 g), Tabasheer (Bambusa arundinacea, 3.5 g), Gule Surkh (Rosa damascena, 1.75 g), and Kafoor (Cinnamomum camphora, 0.25 g). Roghan e Zaitoon will be applied locally once daily after bathing. Patients will be divided into groups: one receiving both the oral compound and local application, and the other receiving Roghan e Zaitoon alone. Levocetirizine 5 mg SOS will be permitted for unbearable symptoms, and the number of tablets consumed per week will be recorded in case report forms for evaluation.